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Seoul virus (SEOV) is a member of the Hantavirus genus (family Bunyaviridae) and an etiological agent of hemorrhagic
fever with renal syndrome. The medium (M) and small (S) gene segments of SEOV encode the viral envelope glycoproteins
and nucleocapsid protein, respectively. We compared the immunogenicity and protective efficacy of naked DNA (pWRG7077),
DNA-based Sindbis replicon (pSIN2.5), and packaged Sindbis replicon vectors (pSINrep5), containing either the M or S gene
segment of SEOV in Syrian hamsters. All of the vectors elicited an anti-SEOV immune response to the expressed SEOV gene
products. Vaccinated hamsters were challenged with SEOV and monitored for evidence of infection. Protection from infection
was strongly associated with M-gene vaccination. A small number of S-gene-vaccinated animals also were protected.
Hamsters vaccinated with the pWRG7077 vector expressing the M gene demonstrated the most consistent protection from
SEOV infection and also were protected from heterologous hantavirus (Hantaan virus) infection. © 1999 Academic Press
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HINTRODUCTION
Hantaviruses are rodent-borne viruses in the Bunya-
iridae family. Hantaan and Seoul viruses (HTNV and
EOV) are etiological agents of hemorrhagic fever with
enal syndrome (HFRS). Hantaviruses are transmitted by
erosolization of infected rodent urine and excreta, and
ach virus is carried principally by one rodent host
HTNV: Apodemus agrarius, SEOV: Rattus norvegicus).
ecause of the rodent host specificity of hantaviruses,
heir distribution is generally limited to the range of the
odent that carries them (HTNV: Asia, SEOV: worldwide)
reviewed in Schmaljohn et al., 1997).
Because hantaviruses cause disease worldwide,
here is a need for development of hantavirus vaccines
reviewed in Gonzalez-Scarano and Nathonson, 1996).
everal approaches have been used to develop candi-
ate hantavirus vaccines. These approaches include
ell-culture or rodent-brain-derived inactivated virus vac-
ines (Lee et al., 1990; Song et al., 1992; Zhu et al., 1994;
u et al., 1996), protein subunit vaccines expressed in
nsect cells (Schmaljohn et al., 1990; Yoshimatsu et al.,
993; Lundkvist et al., 1996), a chimeric hepatitis B virus
ore particle subunit vaccine (Ulrich et al., 1998), recom-
inant vaccinia-vectored vaccines (Schmaljohn et al.,
990, 1992; Xu et al., 1992; Chu et al., 1995), and most
ecently naked DNA-based vaccines (Hooper et al.,
999). One approach that has not been examined is the
1 To whom reprint requests should be addressed. Fax: (301) 619-
1290. E-mail: Kurt.Kamrud@det.amedd.army.mil.
209se of recombinant alphavirus-based expression sys-
ems for hantavirus vaccine development.
Alphaviruses (family: Togaviridae, genus: Alphavirus)
re enveloped viruses that possess a single-strand, pos-
tive-sense RNA genome (Strauss et al., 1994). The de-
elopment of infectious clones for a number of alphavi-
uses has led to the description of several powerful
xpression systems. Expression systems based on a
elf-replicating RNA (replicon) that can be packaged into
iral particles were developed for Semliki Forest virus
SFV), Venezuelan equine encephalitis (VEE) virus, and
indbis virus (SINV) (Xiong et al., 1989; Geigenmuller-
nirke et al., 1991; Liljestrom and Garoff, 1991; Breden-
eek et al., 1993; Pushko et al., 1997). A complete de-
cription of alphavirus replication can be found in
trauss et al. (1994). The SFV and SINV systems also
ere engineered into DNA-based vectors (Dubensky et
l., 1996; Berglund et al., 1998; DiCiommo et al., 1998;
ariharan et al., 1998; Kohno et al., 1998). The DNA-
ased alphavirus vectors drive transcription of the repli-
on RNA from a RNA polymerase II-dependent promoter
cytomegalovirus early promoter). This replicon RNA then
ecomes self replicating and drives expression of a
eterologous gene of interest. Both packaged replicon
ectors and DNA-based replicon vectors have been used
n vaccine studies for a variety of infectious diseases
London et al., 1992; Pugachev et al., 1995; Zhou et al.,
995; Mossman et al., 1996; Pushko et al., 1997; Berglund
t al., 1998; Colombage et al., 1998; Fleeton et al., 1999;
ariharan et al., 1998; Hevey et al., 1998; Tsuji et al.,998). Packaged replicon expression vectors have sev-
0042-6822/99 $30.00
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210 KAMRUD ET AL.ral potential advantages as vaccine vectors: (1) tran-
ient, high-level, protein expression; (2) cytoplasmic
RNA transcription, eliminating potential mRNA splicing
vents that may be associated with nuclear transcription;
nd (3) a broad range of susceptible cells (Frolov et al.,
996). Although the DNA-based replicon vectors do not
hare all of these advantages, the combination of DNA
tability and alphavirus expression capability make them
ttractive vaccine delivery vehicles. For these reasons,
e were interested in testing alphavirus-based expres-
ion vectors as possible hantavirus vaccine vehicles.
In this report we compared the immunogenicity and
rotective efficacy of three different vaccine vectors (na-
ed DNA, DNA-based SINV replicons, and packaged
INV replicons) expressing the SEOV M gene, encoding
he G1 and G2 envelope proteins, or S gene, encoding
he nucleocapsid protein, in a hantavirus hamster infec-
ion model.
RESULTS
ransient expression
All vaccine constructs were analyzed by radio-immu-
oprecipitation (RIP) to assess expression of the SEOV
roteins. DNA vaccine constructs were transfected into
OS cells, and replicon viruses were used to infect
HK-21 cells. The expressed proteins were immunopre-
ipitated with SEOV-specific polyclonal rabbit antisera
nd then analyzed by SDS–PAGE. Proteins of the ex-
ected molecular weight were immunoprecipitated for
EOV G1, G2, and N by using all three expression vectors
Fig. 1). As observed previously, truncated forms of the
ucleocapsid protein were precipitated after transfection
f COS cells with pWRG/SEOV-S DNA (Fig. 1C, lane 2)
Hooper et al., 1999). The truncated forms of N were not
etected in pSIN2.5/SEOV-S DNA transfected or Rep5/
EOV-S virus-infected cells.
mmunogenicity and protective efficacy
f SEOV-S vaccines
Groups of hamsters were vaccinated with control con-
tructs or constructs expressing the SEOV S gene. To
etermine whether vaccinated animals had developed
n antibody response to N, prechallenge sera were an-
lyzed by ELISA. All but one animal vaccinated with a
EOV S gene expressing construct developed anti-N
ntibodies (Table 1). The prechallenge anti-N antibody
eometric mean titers (GMT) for each vector are shown
n parentheses in Table 1. Animals vaccinated with the
SIN2.5/SEOV-S DNA construct had higher anti-N anti-
ody responses than either pWRG/SEOV-S DNA or Rep5/
EOV-S virus-vaccinated animals (Table 1). Only the dif-
erence in anti-N antibody titer between pSIN2.5/SEOV-S
nd pWRG/SEOV-S DNA constructs approached signifi-
ance (GMT: 6400 and 864, respectively, P 5 0.059). uWe also analyzed negative control-vaccinated animals
hat received a lacZ-expressing construct for the devel-
pment of anti-betagalactosidase (bgal) antibodies by
LISA. All animals vaccinated with lacZ-expressing con-
tructs developed anti-bgal antibodies before challenge
data not shown). To determine whether animals vacci-
ated with replicon viruses developed an anti-SINV an-
ibody response, prechallenge sera were analyzed by
nti-SINV ELISA. All of the SIN replicon virus-vaccinated
nimals developed anti-SINV-specific antibodies before
antavirus challenge (data not shown).
To compare the protective efficacy of the SEOV-S vac-
ines, vaccinated animals were challenged with 1000
laque-forming units (PFU) of SEOV 3 weeks after the
inal boost. Twenty-eight days postchallenge the ham-
ters were evaluated for evidence of SEOV infection by
esting sera for the development of anti-G1-G2 antibod-
es with a plaque reduction-neutralization test (PRNT). All
ut one of the animals vaccinated with the pWRG/
EOV-S DNA construct developed SEOV-neutralizing an-
ibodies, indicating that only one pWRG/SEOV-S DNA
accinated hamster was protected from SEOV infection
Table 1). Similar results were noted with pSIN2.5 DNA
onstruct vaccinated hamsters. Two of eight animals
accinated with pSIN2.5/SEOV-S DNA appear to have
een protected from SEOV infection as they did not have
etectable SEOV-neutralizing antibodies (Table 1). None
f the Rep5/SEOV-S virus-vaccinated animals was pro-
ected from SEOV infection as all of the animals had
eutralizing antibodies after challenge (Table 1). All of
he negative control animals developed high levels of
oth anti-N and neutralizing antibodies after SEOV chal-
enge, indicating that the animals were infected (Table 1).
mmunogenicity and protective efficacy
f SEOV-M vaccines
Groups of hamsters were vaccinated with constructs
xpressing the SEOV M gene. To determine whether
accinated animals had developed antibody responses
o the expressed SEOV envelope proteins, prechallenge
era were analyzed by PRNT. All but one animal vacci-
ated with an M gene-expressing construct developed
EOV neutralizing antibodies before challenge (Table 2).
he neutralizing antibody GMT for animals vaccinated
ith pWRG/SEOV-M DNA was significantly higher than
or animals vaccinated with pSIN2.5/SEOV-M DNA (3225
nd 211, respectively. P 5 0.04), but not for Rep5/SEOV-M
irus-vaccinated animals (Table 2).
Comparing the kinetics of neutralizing antibody re-
ponses between DNA and replicon virus-vaccinated
nimals revealed that hamsters vaccinated with pWRG/
EOV-M DNA developed PRNT titers after a single vac-
ination, whereas none of the animals vaccinated with
ep5/SEOV-M virus developed neutralizing antibodies
ntil after the second vaccination (Fig. 2). Moreover,
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211DNA AND ALPHAVIRUS-BASED HANTAVIRUS VACCINESWRG/SEOV-M DNA vaccinated animals had higher neu-
ralizing antibody titers than did Rep5/SEOV-M virus vac-
inated animals at all the time points analyzed (Fig. 2).
To compare the protective efficacy of the SEOV-M
accines, vaccinated animals were challenged with
EOV, and 28 days postchallenge the hamsters were
valuated for evidence of SEOV infection by testing their
era for anti-N antibodies by ELISA. None of the pWRG/
EOV-M gene-vaccinated animals developed detectable
nti-N antibodies after challenge (Table 2). Thus all of
hese animals were protected from SEOV infection. Two
f five animals vaccinated with pSIN2.5/SEOV-M DNA
eveloped anti-N antibodies after challenge, whereas
he remaining three animals did not and thus were pro-
ected from infection (Table 2). A postchallenge ELISA of
ep5/SEOV-M virus vaccinated hamster sera indicated
hat four of five animals developed anti-N antibodies,
ndicating that only one Rep5/SEOV-M virus-vaccinated
nimal was protected from infection (Table 2).
Because animals vaccinated with pWRG/SEOV-M
NA were completely protected from homologous viral
nfection (Table 2), this vaccine was used in a heterolo-
ous hantavirus challenge experiment. Hamsters re-
eived a priming vaccination with either the negative
ontrol plasmid pWRG7077 or pWRG/SEOV-M DNA fol-
owed by two boosts at 3-week intervals. Vaccinated
nimals then were challenged with HTNV 3 weeks after
he final boost. Twenty-eight days postchallenge, the
amsters were evaluated for evidence of HTNV infection.
All of the pWRG/SEOV-M DNA vaccinated animals
eveloped neutralizing antibodies specific for SEOV be-
ore HTNV challenge, with PRNT end-point titers ranging
rom 160 to 5120 (data not shown). In addition, three of
he four pWRG/SEOV-M DNA vaccinated animals had
etectable levels of cross-reactive antibodies capable of
eutralizing HTNV before challenge (Fig. 3). All of the
egative control vaccinated animals developed high
nti-N and neutralizing antibodies after challenge, indi-
ating that all of the animals became infected with HTNV
Fig. 3). In contrast, three of four animals vaccinated with
WRG/SEOV-M DNA had no detectable anti-N antibodies
fter HTNV challenge. One pWRG/SEOV-M DNA vacci-
ated animal developed a detectable anti-N antibody
esponse after HTNV challenge, thus three of four pWRG/
EOV-M DNA vaccinated animals were protected from
TNV infection (Fig. 3).
equential vaccination with Rep5/SEOV-S
nd Rep5/lacZ viruses
To determine whether hamsters vaccinated with one
eplicon virus could be revaccinated with a second rep-
ositions of the SEOV G1, G2, and N proteins are shown on the right of
ach gel. N*, truncated N expression product. Anti-SEOV polyclonalFIG. 1. Radio-immunoprecipitation of SEOV structural proteins ex-
ressed in vitro from SINrep5 (A), pSIN2.5 (B), and pWRG7077 (C)
xpression vectors. Lane 1, SEOV M gene expression products. Lane 2,
EOV S gene expression product. Lane 3, antibody negative control.abbit sera was used to precipitate SEOV proteins.
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212 KAMRUD ET AL.icon virus, a selected group of animals were sequen-
ially vaccinated with two different recombinant replicon
iruses. Hamsters vaccinated with Rep5/SEOV-S virus
nd then challenged with SEOV were inoculated with
3 106 IFU of Rep5/lacZ virus ;8 weeks after the SEOV
hallenge. Sera were collected 4 weeks after Rep5/lacZ
irus vaccination and analyzed for anti-bgal antibodies
y ELISA. The anti-N, anti-SINV, and anti-bgal ELISA
esponses for individual animals before and after se-
uential vaccination with Rep5/lacZ virus are shown in
able 3. For comparison, the same antibody responses
ere determined for control animals (SINV naive) after
ne vaccination with Rep5/lacZ virus (Table 3). Three of
T
Serological Responses and Protection of Ha
Vaccine Hamster
Anti-N E
Prec
WRG/SEOV-S DNAe 1 200
(GMT 864) f 2 100
3 ,100
4 3,200
5 200
6 400
7 25,600
8 25,600
9 3,200
SIN2.5/SEOV-S DNAe 1 6,400
(GMT 6,400) f 2 6,400
3 6,400
4 6,400
5 6,400
6 12,800
7 6,400
8 3,200
ep5/SEOV-S viruse 1 1,600
(GMT 1,600) f 2 1,600
3 800
4 3,200
WRG7077 DNAe n 5 9g ,100
SIN2.5/lacZ DNAe n 5 5g ,100
ep5/lacZ virus j n 5 6g ,100
a ELISA endpoint titers are the reciprocal serum dilution that had OD
b PRNT values are the reciprocal serum dilution that reduces plaque
c pre: prechallenge serum sample. post: postchallenge serum samp
d 2, animal was protected from SEOV infection; 1, animal was not
e Hamsters were vaccinated three times at 3-week intervals.
f Prechallenge anti-N antibody geometric mean titers for each vecto
g Number of animals vaccinated with negative control construct.
h Geometric mean antibody titer for negative control animals.
i Range of negative control ELISA or PRNT endpoint titers.
j Hamsters were vaccinated three times at 4-week intervals.he four animals that received a secondary vaccination pith Rep5/lacZ virus developed anti-bgal antibodies, and
ll of the control animals vaccinated with Rep5/lacZ virus
eveloped anti-bgal antibodies (Table 3). An anti-bgal
ntibody response was elicited even though the animals
ad preexisting antibody to SINV, indicating that sequen-
ial vaccination with two different SINV replicons was
ossible.
DISCUSSION
Previously, we showed that hamsters vaccinated with
naked DNA vector expressing the SEOV M gene were
rotected from infection with SEOV, whereas those ex-
Vaccinated with SEOV S Gene Constructs
PRNTb
Infectiondost Pre Post
,600 ,20 40,960 1
,400 ,20 40,960 1
,600 ,20 20,480 1
,800 ,20 5,120 1
,200 ,20 81,920 1
,800 ,20 5,210 1
,800 ,20 ,20 2
,800 ,20 40,960 1
,600 ,20 320 1
,600 ,20 5,120 1
,200 ,20 1,280 1
,600 ,20 10,240 1
,200 ,20 40,960 1
,400 ,20 40 1
,200 ,20 20,480 1
,400 ,20 ,20 2
,200 ,20 ,20 2
,600 ,20 160 1
,400 ,20 1,280 1
,600 ,20 2,560 1
,400 ,20 2,560 1
,962h ,20 10,240h 1
–6,400) i (1,280–40,960) i
,675h ,20 8,914h 1
–51,200) i (5,120–20,480) i
,269h ,20 3,225h 1
–3,200) i (1,280–10,240) i
m values greater than control serum 1 3 standard deviations.
er by 80%.
ed from SEOV infection.ABLE 1
msters
LISAa
P
25
6
1
12
3
12
12
12
1
25
3
25
51
6
51
6
3
1
6
1
6
2
(1,600
3
(800
1
(800
450 n
numb
le.
protect
r.ressing the SEOV S segment were not (Hooper et al.,
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213DNA AND ALPHAVIRUS-BASED HANTAVIRUS VACCINES999). The data presented in this report confirm and
xtend those results and further demonstrate the poten-
ial of two other nucleic-acid-based vectors as hantavirus
accines.
Although all three systems expressed hantavirus pro-
eins and were immunogenic in hamsters, we noted
ome qualitative and quantitative differences. Compar-
ng gene expression levels between the two DNA-based
ectors, pWRG7077 and pSIN2.5 in vitro revealed that the
WRG7077 constructs consistently expressed higher lev-
ls of protein than pSIN2.5 constructs in cell culture. This
esult was unexpected based on the self-amplifying na-
ure of SIN replicon RNAs (Dubensky et al., 1996; Hari-
aran et al., 1998). In addition, the difference in expres-
ion levels between the two vectors was not due to the
SIN2.5 vector not functioning as a replicon in tissue
ulture, as we were able to demonstrate that a DNA-
ased SINV replicon vector with a deletion in the SINV
onstructural gene region was unable to express SEOV
enes (data not shown). However, reduced expression in
itro did not always correlate with reduced immune re-
ponse in vivo. This was best illustrated by a comparison
f the pWRG/SEOV-S and pSIN2.5/SEOV-S DNA con-
tructs. Assay of N expression revealed that pWRG/
EOV-S DNA transfected COS cells expressed more N
T
Serological Responses and Protection of Ha
Vaccine Hamster
Anti-N
Prec
WRG/SEOV-M DNAd 1 ,100
(GMT 3,225) f 2 ,100
3 ,100
4 ,100
5 ,100
6 ,100
SIN2.5/SEOV-M DNAe 1 ,100
(GMT 211) f 2 ,100
3 ,100
4 ,100
5 ,100
ep5/SEOV-M virusg 1 ,100
(GMT 1,270) f 2 ,100
3 ,100
4 ,100
5 ,100
a ELISA endpoint titers are the reciprocal serum dilution that had OD
b PRNT values are the reciprocal serum dilution that reduced plaque
c pre, prechallenge serum sample; post, postchallenge serum samp
d 2, Animal was protected from SEOV infection. 1: Animal was not
e Hamsters were vaccinated three times at 3-week intervals.
f Prechallenge neutralizing antibody geometric mean titers for each
g Hamsters were vaccinated three times at 4-week intervals.han did pSIN2.5/SEOV-S DNA transfected cells, even vhen plasmid copy number (pSIN2.5 is about three
imes as large as pWRG7077) and transfection efficiency
ere controlled for (data not shown). However, despite
he relatively low in vitro expression level, hamsters
accinated with pSIN2.5/SEOV-S DNA developed higher
MTs to N than did animals vaccinated with pWRG/
EOV-S DNA (6309 and 857, respectively P 5 0.059).
erglund et al. (1998) noted a similar phenomenon (low
n vitro expression, high in vivo immune response) when
omparing a conventional RNA-polymerase-II-depen-
ent, promoter-based plasmid and a DNA-based SFV
ector, both expressing influenza A virus genes. Others
uggest that the enhanced immune response elicited by
NA-based alphavirus vectors expressing certain genes
ay be due to vector-mediated cell death or induction of
nterferons as a result of alphavirus replication within
ransfected cells (Berglund et al., 1998; Hariharan et al.,
998). In contrast to the results with the S segment
onstructs, pSIN2.5/SEOV-M DNA constructs failed to
licit higher antibody responses than pWRG/SEOV-M
NA constructs (PRNT GMT 211, and 3225, respectively
5 0.04). These data suggest that the level of the
ntibody response elicited from a DNA-based alphavirus
ector may vary dependent on the gene expressed.
Three of four animals vaccinated with Rep5/SEOV-S
Vaccinated with SEOV M Gene Constructs
a PRNTb
InfectiondPost Pre Post
,100 5,120 10,240 2
,100 2,560 2,560 2
,100 2,560 5,120 2
,100 5,120 10,240 2
,100 2,560 2,560 2
,100 2,560 2,560 2
200 320 1,280 1
800 20 2,560 1
,100 640 320 2
,100 80 320 2
,100 1,280 1,280 2
3,200 ,20 2,560 1
400 5,120 2,560 1
200 2,560 640 1
200 640 1,280 1
,100 1,280 320 2
m values greater than control serum 1 3 standard deviations.
er by 80%.
ed from SEOV infection.ABLE 2
msters
ELISA
450 n
numb
le.
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vector.irus and subsequently vaccinated with Rep5/lacZ virus
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214 KAMRUD ET AL.eveloped anti-bgal antibodies even in the presence of
nti-SINV antibodies. The anti-SINV antibody response
licited in replicon virus-vaccinated animals was most
ikely due to the presence of replication competent virus
n the replicon virus stocks (data not shown). Mice se-
uentially vaccinated with VEE replicons expressing in-
luenza virus hemagglutinin and Lassa virus nucleocap-
id also were able to develop antibodies to both proteins,
lthough these animals either had no or very low levels
f preexisting anti-VEE antibodies (Pushko et al., 1997).
nimals with no preexisting SINV immunity developed
uch higher end-point anti-bgal antibody responses af-
er a single Rep5/lacZ virus vaccination than did the
ep5/lacZ virus sequentially vaccinated animals, sug-
esting that preexisting SINV immunity may have limited
he anti-bgal response in the sequentially vaccinated
nimals.
Because no animal model of disease is known for
antaviruses, our protection model was based on detec-
ion of antibodies to non-vaccine-derived viral proteins
fter challenge. This is an extremely rigorous definition
f protection because it is based on sterile immunity. For
xample, one Rep5/SEOV-M virus-vaccinated animal had
ow but detectable anti-N antibodies after challenge de-
pite having a high prechallenge neutralizing antibody
iter (5120) and demonstrating a drop in neutralizing
ntibody after challenge (2560). It is possible that this
FIG. 2. Analysis of the development of neutralizing antibodies over
amster serum was collected before vaccination (prebleed) and 3 (pW
nalyzed by PRNT. Each time point represents the PRNT geometri
ep5/SEOV-M virus-vaccinated animals.nimal developed an immune response to the protein cresent in the challenge inoculum even though replica-
ion may not have occurred. Therefore it is difficult to
efinitively assess whether animals that display this type
f immune profile are productively infected with SEOV.
Previously, we were unable to demonstrate that ham-
ters vaccinated with pWRG/SEOV-S DNA alone could
e protected from SEOV infection (Hooper et al., 1999). In
hat study, pWRG/SEOV-S DNA vaccination data did re-
eal an about fivefold reduction in postchallenge PRNT
iter in SEOV S gene-vaccinated animals as compared
ith negative control-vaccinated/SEOV-challenged ani-
als (Hooper et al., 1999). These data suggest that,
lthough SEOV S-vaccinated animals became infected,
he infection may have been limited as compared with
he infection in negative control animals (Hooper et al.,
999). The data presented here confirm those results in
hat one of nine hamsters vaccinated with pWRG/SEOV-S
NA and two of eight hamsters vaccinated with pSIN2.5/
EOV-S DNA were protected from SEOV infection. It may
e that the larger number of animals tested in this study
llowed us to detect individuals that had developed a
rotective immune response. It is also possible that
hese animals did not receive an infectious dose of SEOV
t challenge, thus resulting in a false-positive appear-
nce of protection. This possibility is unlikely considering
hat all of the control animals became infected after
eceiving the same SEOV challenge dose. There was no
pWRG/SEOV-M DNA and Rep5/SEOV-M virus-vaccinated hamsters.
OV-M) or 4 (Rep5/SEOV-M) weeks after each vaccination (vacc) and
titer (GMT) for either six pWRG/SEOV-M DNA vaccinated or fivetime in
RG/SE
c meanlear correlation of prechallenge anti-N antibody titer
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215DNA AND ALPHAVIRUS-BASED HANTAVIRUS VACCINESnd protection. That is, some animals with anti-N ELISA
iters as high as 25,600 were not protected from infec-
ion. These data suggest that anti-N antibody levels are
ot good markers of a protective immune response.
thers have demonstrated the protective capacity of
antavirus N (Schmaljohn et al., 1990; Xu et al., 1992;
oshimatsu et al., 1993; Lundkvist et al., 1996; Ulrich et
l., 1998); however, the most successful approaches
ave been with recombinant baculovirus-infected cell
ysates containing N or chimeric hepatitis B virus core
articles that display N epitopes. (Schmaljohn et al.,
990; Lundkvist et al., 1996; Ulrich et al., 1998). Vaccina-
ion with vaccinia virus recombinants expressing N only
artially protected animals from infection (Schmaljohn et
l., 1990; Xu et al., 1992). Cell-mediated immunity is
elieved to be important for clearing a hantavirus infec-
ion (Nakamura et al., 1985; Asada et al., 1987, 1989) and
ell-mediated immunity to N as well as the envelope
roteins have been demonstrated (Yoshimatsu et al.,
993; Ennis et al., 1997). Analysis of the immune re-
ponse elicited in animals vaccinated with recombinant
FIG. 3. Protection from HTNV challenge. Prechallenge and postchal-
enge anti-N ELISA and PRNT titers are shown for control (pWRG7077)
nd pWRG/SEOV-M vaccinated animals. ELISA values are reciprocal
erum dilution end-point titers. PRNT values are the reciprocal serum
ilution that reduced plaque number by 50%.compared with the immune response in animals vac- qinated with vectors that produce N endogenously will
e required to determine what the critical factors are that
esult in N protein-specific protection.
All of the SEOV M gene-expressing vectors were ca-
able of eliciting a neutralizing antibody response in
amsters but only the pWRG/SEOV-M DNA vector was
apable eliciting sterile immunity in all SEOV-challenged
nimals. In addition, a comparison of when animals
eveloped neutralizing antibodies after DNA-based or
IN replicon virus-based vaccination with the M gene
evealed that the DNA-vaccinated animals developed
eutralizing antibodies not only earlier but also to higher
nd-point titers. Based on these results, the pWRG/
EOV-M DNA vector was used in a HTNV cross-protec-
ion study.
These results show for the first time, that DNA vacci-
ation with the SEOV M gene can elicit a cross-protec-
ive immune response against HTNV infection. These
ata agree with protection data derived from gerbils
accinated with a vaccinia-vectored SEOV M gene and
hen challenged with HTNV (Xu et al., 1992) and with data
erived from live hantavirus cross-protection studies in
odents (Yamanishi et al., 1988; Yoshimatsu et al., 1993;
u et al., 1996). Three of four pWRG/SEOV-M DNA vac-
inated animals had detectable HTNV-neutralizing anti-
odies before challenge and were protected from infec-
ion with HTNV, although all had prechallenge SEOV-
eutralizing antibodies. The animal that was not
rotected from heterologous viral infection had no de-
ectable prechallenge HTNV-neutralizing antibodies and
lso had the lowest prechallenge neutralizing antibody
iter to SEOV (PRNT 5 160). The level of anti-SEOV
eutralizing antibodies in the animal that was not pro-
ected from HTNV challenge was less than that required
o induce sterile immunity but it appeared to be high
nough to limit HTNV replication as indicated by a much
ower anti-N antibody response (1:100) than those of
egative controls (range 800–6400). Nevertheless our
indings demonstrate the feasibility of a DNA-based han-
avirus vaccine that can afford cross-protective potential.
Although our studies using recombinant DNA-based
accines demonstrated cross-protection in hamsters be-
ween SEOV and HTNV, a vaccinia-vectored vaccine for
TNV did not protect against Puumala virus (Chu et al.,
995). Consequently, these data suggest that a multiva-
ent vaccine will be required for protection from all of the
athogenic members of the Hantavirus genus. An impor-
ant first step in this process is determining what vector
ystem to use in hantavirus vaccine studies. Based on
he data presented here, we believe that a DNA-based
pproach shows great promise for multivalent hantavirus
accine development. In addition, these data begin to
efine the minimal complement of hantavirus genes re-
uired in a multivalent DNA-based vaccine.
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iruses, cells, and medium
SEOV, strain SR-11 (Kitamura et al., 1983), and HTNV,
train 76-118 (Lee et al., 1978), were propagated in Vero
6 cells (VERO C1008;ATCC CRL 1586). SINV (strain
Rsp) (Strauss et al., 1984), and SIN replicon viruses
ere produced in BHK-21 cells (ATCC CCL-10). Transient
xpression experiments were performed in either
HK-21 cells or COS cells (COS-7; ATCC CRL1651). Cells
ere maintained in Eagle’s minimal essential medium
ith Earle’s salts (EMEM) containing 10% fetal bovine
erum, 10 mM HEPES pH 7.4; and antibiotics [penicillin
100 U/ml), streptomycin (100 mg/ml), and gentamicin (50
g/ml)] (cEMEM).
lasmid constructs
RT–PCR and cloning of the M and S genome segments
f SEOV were described previously (Arikawa et al., 1990).
Naked DNA vectors.The pWRG/SEOV-M and SEOV-S
NA vectors were described previously (Hooper et al.,
999) (Fig. 4A).
DNA-based SINV vector. Construction of the pSIN2.5
NA vector was described elsewhere (Hariharan et al.,
998) (Fig. 4B). The pSIN2.5/lacZ DNA construct was
rovided by Chiron Technologies, San Diego, CA. PCR
T
Sequential SINV Replicon V
ELISAa Hamster 1 Hamster 2
Three vaccinations
N 1,600 1,600
SINV 3,200 6,400
bgal ,50 ,50
Single vaccination with Rep5/lacZ viru
N 400 800
SINV 400 3,200
bgal 100 800
Single vaccination with R
ELISA Hamster 5 Hamster 6
N ,50 ,50
SINV 800 6,400
bgal 3,200 800
a Antigen-specific ELISA.
b GMT: geometric mean ELISA titer specific for each antigen.
c ELISA titers for the indicated antigens were determined 3 weeks a
d ELISA titers for the indicated antigens were determined 4 weeks af
ep5/SEOV-S virus.
e ELISA titers for the indicated antigens were determined 4 weeks arimers were designed to amplify the SEOV M and S (ene open reading frames (ORFs) with unique XhoI and
otI restriction sites at the 59 and 39 ends, respectively.
he XhoI/NotI-digested SEOV PCR products then were
igated into XhoI/NotI-linearized pSIN2.5 DNA to produce
he pSIN2.5/SEOV-M and pSIN2.5/SEOV-S DNA con-
tructs.
SINV replicon vector. The pSINrep5 vector (Invitrogen,
arlsbad, CA) (Fig. 4C) and pSINrep5/lacZ construct
ere described previously (Bredenbeek et al., 1993). The
EOV M and S gene ORFs were subcloned into the XbaI
ite of pSINrep5 to produce pSINrep5/SEOV-M and
SINrep5/SEOV-S. Defective helper plasmid pDH-BB
Bredenbeek et al., 1993) was used to supply the SINV
tructural proteins in trans to generate packaged repli-
ons.
eplicon virus production
The SINV replicon vectors and defective helper
NAs were linearized to allow run-off transcription.
ranscription reactions were carried out with an In-
itroScript CAP SP6 in vitro transcription kit (Invitro-
en) as described by the manufacturer. The tran-
cribed RNAs were used without treatment with
Nase or further purification. A BioRad (Hercules, CA)
ene pulser was used for all electroporations. BHK-21
ells were suspended in phosphate-buffered saline,
ion of Individual Hamsters
Hamster 3 Hamster 4 GMTb
ep5/SEOV-S virusc
400 800 951
400 1,600 1,903
,50 ,50 25
p5/SEOV-S virus vaccinated animalsd
3,200 800 951
200 1,600 800
200 ,50 141
Z virus (naive hamsters)e
Hamster 7 Hamster 8 GMT
,50 ,50 25
800 100 800
3,200 3,200 2,263
final Rep5/SEOV-S virus vaccination.
gle Rep5/lacZ virus vaccination in animals previously vaccinated with
ingle Rep5/lacZ virus vaccination in SINV naive hamsters.ABLE 3
accinat
with R
s in Re
ep5/lac
fter the
ter a sinpH 7.4) (PBS) at a density of 1 3 107 cells/ml, and 0.8
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217DNA AND ALPHAVIRUS-BASED HANTAVIRUS VACCINESl of the cell suspension combined with ;10 mg each
f replicon and helper RNAs was used per electropo-
ation. Each cell/RNA mixture was transferred to
.4-mm gap cuvettes (BioRad) and pulsed three times
ith the electroporator conditions set at 1.1 kV and
5uF. Packaged replicon viruses were harvested
6–48 h postelectroporation and purified by centrifu-
ation through a 20% sucrose cushion as described
reviously (Kamrud et al., 1995). Replicon viruses gen-
rated were designated Rep5/X virus where X repre-
ented the SEOV gene cloned into the pSINrep5 con-
truct. Purified replicon viruses were resuspended in
terile PBS and titrated by immunofluorescent anti-
ody (IFA) assay as described previously (Kamrud et
l., 1995).
nimal vaccination
Outbred, 6- to 8-week-old, golden Syrian hamsters
Charles River) received a priming vaccination followed
y two boosts at 3- or 4-week intervals. Animals vacci-
ated with DNA constructs received ;3.0 mg DNA de-
ivered by gene gun per vaccination as described previ-
usly (Hooper et al., 1999). Animals vaccinated with rep-
icon viruses received ;1 3 106/infectious units (IFU) of
irus, diluted in sterile PBS, by subcutaneous inoculation
FIG. 4. Vaccine expression vectors. (A) pWRG7077, (B) pSIN2.5, (C) pS
f interest; BgH, bovine growth hormone transcription terminator; PRE, h
epatitis delta virus ribozyme sequence; nsP1–4, Sindbis nonstructu
anamycin resistance gene; AmpR, ampicillin resistance gene. Open aer vaccination. bLISA
The method for detecting hantavirus N-specific anti-
odies was described previously (Elgh et al., 1997;
ooper et al., 1999). Briefly, amino acids 1–117 of SEOV
were expressed as a histidine-tagged fusion protein in
scherichia coli. Affinity-purified protein diluted in car-
onate buffer (pH 9.6) was coated onto 96-well ELISA
lates (Costar, Cambridge, MA) overnight at 4°C. Ham-
ter sera then were diluted in PBS containing 3% goat
erum, 5% skim milk, 1% E. coli lysates, and 0.05% Tween
0 and analyzed for the presence of anti-N specific
ntibodies by ELISA. Sera from hamsters vaccinated
ith control constructs that expressed the lacZ gene
ere analyzed for the development of anti-bgal antibod-
es. For these studies, ELISA plates were coated with
00 hg/well of purified bgal protein (Boehringer Mann-
eim, Indianapolis, IN) in carbonate buffer overnight at
°C. Animals vaccinated with recombinant SIN replicon
iruses were analyzed for the development of anti-SINV
ntibodies. SINV (strain HRsp) purified on a 20–60%
ucrose gradient was diluted 1:500 in carbonate buffer
nd coated onto ELISA plates overnight at 4°C. Horse-
adish peroxidase-conjugated goat, anti-hamster sec-
ndary antibody (diluted 1:10,000) [Kirkegaard & Perry
aboratories (KPL), Gaithersburg, MD] and tetra-methyl-
CMV, cytomegalovirus immediate early promoter sequence; GOI, gene
s B virus posttranscriptional regulatory element; p(A), poly (A) tract; dv,
tein genes; SP6, SP6 RNA polymerase promoter sequence; KanR,
epresents Sindbis virus 26S subgenomic promoter.INrep5.
epatiti
ral proenzidine substrate (KPL) were used in all ELISA exper-
i
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218 KAMRUD ET AL.ments as described previously (Hooper et al., 1999). The
olorimetric reaction was stopped by adding stop solu-
ion (KPL), and the optical density (OD), at 450 nm, was
easured. End-point titers were determined as the high-
st dilution with an OD greater than the mean OD value
f negative control serum samples (pWRG7077 DNA,
SIN2.5/lacZ DNA, or Rep5/lacZ virus-vaccinated ani-
als) (diluted 1:100) plus 3 standard deviations.
adio-immunoprecipitation (RIP)
RIP analysis of naked DNA constructs (pWRG7077 or
SIN2.5) was conducted in COS cells. COS cells grown
n 25 cm2 flasks were transfected with 8 mg of plasmid
NA with FuGENE 6 (Boehringer Mannheim) as de-
cribed by the manufacturer. RIP analysis of SINV repli-
on constructs was conducted in BHK-21 cells. BHK-21
ells grown in 25 cm2 flasks were infected with replicon
iruses at a m.o.i. of 3. After 24 h (48 h for pSIN2.5 DNA
onstructs), the cells were radiolabeled with 200 mCi 35S
romix (Amersham, Arlington Heights, IL) per flask. The
ells were labeled for 3 h, cell lysates were produced
ith Zwittergent (Calbiochem-Novabiochem Corp., La
olla, CA) lysis buffer, and SEOV proteins were immuno-
recipitated with rabbit anti-SEOV polyclonal sera as
escribed previously (Schmaljohn et al., 1997; Kamrud et
l., 1998).
laque-reduction neutralization test (PRNT)
Neutralization assays were performed as previously
escribed (Hooper et al., 1999). All serum samples were
eat inactivated (56°C, 30 min), and neutralization as-
ays were carried out in the presence of (5%) guinea pig
omplement (Accurate Chemical and Scientific Corp.,
estbury, NY).
antavirus challenge
Hamsters were inoculated with 1000 PFU of either
TNV or SEOV intramuscularly as previously described
Hooper et al., 1999). Twenty-eight days after challenge,
erum samples were evaluated for the presence of anti-
TNV or anti-SEOV antibodies. Because hantavirus neu-
ralizing antibodies are directed at the envelope proteins
G1 and G2) (Dantas et al., 1986; Arikawa et al., 1989),
era were analyzed by PRNT to follow the anti-glycopro-
ein antibody response. Anti-N protein-specific ELISA
as performed to analyze the anti-nucleocapsid immune
esponse in vaccinated animals. Because there is no
isease model available for hantaviruses, we evaluated
nstead whether our vaccines could protect against in-
ection. An animal was considered infected if antibodies
o viral proteins other than the vaccine immunogen were
etected after viral challenge. FACKNOWLEDGMENTS
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